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The purpose of this meta-analysis was to examine whether 
association studies between attention deﬁcit/hyperactivity dis­
order (AD/HD) and the dopamine receptor 4 gene 7-repeat 
(DRD4 7R) allele vary systematically based on study character­
istics. A total of 27 empirical studies with 28 distinct samples 
using either case–control or family-based association analyses 
were included. Consistent with previous meta-analytic work 
[Gizer et al. (2009), Hum Genet 126:51–90], the DRD4 7R allele 
was associated with AD/HD across studies (OR ¼ 1.33; 95% 
CI ¼ 1.16–1.53, z ¼ 4.04, P ¼ 0.00005) and there was signiﬁcant 
systematic variability among studies (Q ¼ 54.24; P ¼ 0.001; 
I2 ¼ 50.22). To account for the variability among studies, sample 
and study level covariates were examined. No differences in 
overall effect size emerged between family-based and case– 
control studies. However, the risk allele frequency in the control 
population accounted for a signiﬁcant portion of the variance 
in overall effect size within case–control studies. In addition, 
evidence for the association between the DRD4 7R allele and 
distinct AD/HD subtypes emerged across family-based and 
case–control studies. The proportion of AD/HD, combined type 
individuals within the AD/HD sample was associated with a 
signiﬁcant increase in the magnitude of association between the 
DRD4 7R allele and AD/HD. Conversely, an increase in the 
proportion of AD/HD, predominantly inattentive type individ­
uals within the AD/HD sample was associated with a decrease in 
study effect size. Implications regarding AD/HD etiological and 
phenotypic heterogeneity are discussed. 
Key words: attention; hyperactivity; dopamine; genetics; meta­
regression 
INTRODUCTION 
Attention deﬁcit/hyperactivity disorder (AD/HD) is characterized 
by persistent, pervasive and developmentally inappropriate levels of 
inattention, hyperactivity–impulsivity, or both that lead to clini­
cally signiﬁcant impairment. The AD/HD phenotype is highly 
heterogeneous and there has been much debate on how to appro­
priately reduce phenotypic heterogeneity by creating diagnostic 
subtypes or separate disorders [e.g., Milich et al., 2001]. According 
to the DSM-IV, individuals are sub-grouped into AD/HD com­
bined type (AD/HD-C) if they exhibit high levels of both inatten­
tion and hyperactive-impulsive symptoms; AD/HD predominantly 
inattentive type (AD/HD-I) if they display excessive inattention 
only; and AD/HD predominantly hyperactive-impulsive type 
(AD/HD-HI) if they show excessive hyperactive-impulsive symp­
toms only. AD/HD-I is the most prevalent subtype in community 
samples [e.g., Gaub and Carlson, 1997; DuPaul et al., 1998]. In 
contrast, AD/HD-C tends to be the most prevalent subtype in 
clinical populations, outnumbering AD/HD-I by 2:1 and AD/HD­
HI by 3:1 [Lahey et al., 1994]. Given that AD/HD-HI is the least 
prevalent subtype and lacks temporal stability [Lahey et al., 2005], 
this subtype will not be further discussed in detail. 
Although the speciﬁc etiology is not completely understood, 
several factors associated with the development of AD/HD have 
been identiﬁed. Evidence from family, twin, and adoption studies 
suggest that genetic factors substantially contribute to the devel­
opment of AD/HD [heritability estimate ¼ 0.76; Faraone et al., 
2005]. Molecular genetics research has attempted to identify genes 
that increase susceptibility for the disorder. Consistent with the 
dopamine deﬁcit hypothesis of AD/HD etiology [Levy, 1991], genes 
associated with the dopamine system (e.g., DAT1 and DRD4) have 
been major foci of study. The dopamine receptor 4 gene 7 repeat 
(DRD4 7R) allele has been widely studied and is one of the most 
strongly associated alleles with AD/HD [OR ¼ 1.33; Gizer et al., 
2009]. 
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The DRD4 gene is a 48-bp VNTR on exon 3, located on 
chromosome 11p15.5 [Gelernter et al., 1992; Petronis et al., 
1993]. Allele variants produce structural differences in the 3rd 
intracellular loop of the D4 receptor, which belongs to the D2 
receptor family, and couples to pre- and post-synaptic G-protein 
effectors. D4 receptors are found at high densities in the frontal 
cortex, amygdala, hippocampus, hypothalamus, and mesencepha­
lon [Van Tol et al., 1991; O’Malley et al., 1992], and the 7R allele may 
be associated with a sub-sensitive post-synaptic D4 receptor or 
hypofunctioning of mesolimbic and mesocortical dopamine 
branches [Missale et al., 1998]. Ten alleles (2R-11R) have been 
identiﬁed in the global population [Seeman and Van Tol, 1994] 
with the 2R, 4R and 7R alleles being the most common variants. 
DRD4 allele frequency varies substantially between ethnic 
groups [Chang et al., 1996]. Generally, the 7R allele is 
relatively most prevalent in Central and South American popula­
tions, less prevalent in European Ancestry populations, and least 
prevalent in Asian populations [Van Tol et al., 1991; Chang 
et al., 1996]. 
Despite an overall association between the DRD4 7R allele and 
AD/HD, a recent meta-analysis [Gizer et al., 2009] found that the 
magnitude of the association varies substantially across studies. 
Though many different potential sources of heterogeneity exist, 
researchers have focused primarily on AD/HD subtype and, to a 
lesser extent, study methodology. 
Factors Accounting for Heterogeneity in the 
Association of DRD4 7R Allele With AD/HD 
AD/HD subtype. According to Sagvolden et al. [2005], hypo-
functioning in the mesolimbic dopaminergic pathway is related to 
hyperactivity–impulsivity, and hypofunctioning in the mesocort­
ical dopaminergic pathway is related to poor executive functioning 
and attentional processes. Given that the DRD4 7R allele is impli­
cated in the hypofunctioning of both dopaminergic pathways 
[Missale et al., 1998], it is likely that the DRD4 7R allele would 
give rise to both inattention and hyperactivity–impulsivity symp­
toms. Therefore, the DRD4 7R allele may be more strongly associ­
ated with individuals with AD/HD-C compared to AD/HD-I. 
Furthermore, youth with AD/HD and the 7R allele tend to have 
a quicker response time [Manor et al., 2002; Langley et al., 
2004] and a more consistent reaction time to target stimuli 
than AD/HD youth without the 7R allele [Swanson et al., 
2000; Manor et al., 2002; Bellgrove et al., 2005]. Therefore, it is 
unlikely that the DRD4 7R allele is associated with AD/HD-I, as 
a subset of individuals with AD/HD-I has a slowed reaction time 
to target stimuli [e.g., Dereﬁnko et al., 2008]. However, ﬁndings 
from studies that have examined the differential association 
between the DRD4 7R allele and AD/HD subtypes and AD/HD 
symptom dimensions have been inconsistent [Rowe et al., 1998, 
2001; McCracken et al., 2000; Todd et al., 2001; Frank et al., 
2004]. Similarly, ﬁndings on the association between single nucle­
otide polymorphisms in the DRD4 promoter region and AD/HD 
symptom dimensions have also been inconsistent [Lasky-Su et al., 
2007, 2008]. 
A few researchers have examined the association of the DRD4 7R 
allele and AD/HD with the presence or absence of oppositional 
deﬁant disorder (ODD) and found that the DRD4 7R allele tends to 
be more strongly associated with AD/HD when comorbid with 
ODD [Holmes et al., 2002; Kirley et al., 2004]. 
Such inconsistent ﬁndings may be related to the small sample 
sizes and limited stability of the DSM-IV AD/HD subtypes overtime 
[Lahey et al., 2005]; thus, this question may be better addressed in 
the context of a mega-sample or meta-analysis [Faraone, 2008]. For 
example, by combining 14 independent samples, Lowe et al. [2004] 
demonstrated that the DRD5 148 bp allele was associated with AD/ 
HD-C and AD/HD-I but not AD/HD-HI. Similarly, I.D. Waldman 
(personal communication, September 8, 2009) used summary 
statistics between studies and found evidence for a stronger rela­
tionship between DAT1 and 5HTTLPR risk alleles and AD/HD-C 
compared to AD/HD-I. 
Study methodology. Others have taken a between-studies ap­
proach and explored whether study methodology moderates the 
magnitude of effect size. Li et al. [2006] explored the heterogeneity 
in effect sizes between association studies using study design 
(case–control vs. family-based) as a moderating variable and 
found that case–control studies had a signiﬁcantly higher mean 
effect size than family-based studies. The authors suggest that 
such differences may be the result of population stratiﬁcation 
[Cardon and Bell, 2001] or differences between subjects 
ascertained from case–control and family-based study designs 
[West et al., 2002]. 
Summary and Hypotheses 
Given the differences in samples, assessment methodology and 
study design, systematic variation in observed effect sizes [Gizer 
et al., 2009] is likely to result from a combination of sample and 
study characteristics. Building from previous meta-analyses that 
have found signiﬁcant variation in the association between AD/HD 
and the DRD4 7R allele [Li et al., 2006; Gizer et al., 2009], the 
purpose of this study was to examine how certain sample and 
study variables may moderate the association between DRD4 7R 
allele and AD/HD. Of particular interest is the distribution of AD/ 
HD subtypes in identiﬁed samples. Thus, based on AD/HD etio­
logical theory [Sagvolden et al., 2005], the following hypothesis was 
made: 
An increase in the proportion of individuals with AD/HD-C in the 
AD/HD sample would be associated with an increase in magni­
tude of association between AD/HD and the DRD4 7R allele. 
Conversely, an increase in the proportion of AD/HD-I in the AD/ 
HD sample will be associated with a decrease in magnitude of 
association between AD/HD and the DRD4 7R allele. 
In addition, several exploratory moderators of the relationship 
between DRD4 7R allele and AD/HD were examined. Given that 
additional studies have been published since Li et al. [2006], the 
moderator of study design (case–control and family-based) was re­
examined. The allele frequency in cases and controls, the mean age 
of the AD/HD sample, the proportion of males in the AD/HD 
sample, diagnostic classiﬁcation system, and sample ethnicity were 
also examined as potential moderators to the relationship between 
DRD4 7R and AD/HD. 
MATERIALS AND METHODS 
Literature Search 
First, computer searches were conducted using the PubMed and 
PsycInfo search engines. Keywords associated with AD/HD phe­
notype (ADHD, inattention and hyperactivity) were crossed with 
words associated with the DRD4 7R allele (DRD4, D4DR, dopa-
mine receptor) to identify relevant studies that were published 
between January 1990 and July 2009. The author reviewed abstracts 
and if the study included an AD/HD or related sample (e.g., 
hyperkinetic disorder) and had genotyped DRD4 then the full-text 
article were retrieved. Next, the reference section of each full text-
article, including previous meta-analyses [Faraone et al., 2001, 
2005; Maher et al., 2002; Li et al., 2006; Gizer et al., 2009], were 
reviewed to ﬁnd additional studies that were not identiﬁed in the 
computer search. All together, this approach yielded 44 studies that 
provided data on the association between AD/HD and DRD4 7R 
allele. Using a developed protocol (available upon request), data 
from each study was extracted on two separate occasions by this 
study’s author. Next, the separate protocols for each study were 
compared, and the corresponding author(s) for each identiﬁed 
study were sent the protocol, asked to clarify any discrepancies, and 
asked to provide supplementary information including raw data to 
compute the effect size and values for moderating variables of 
interest. No additional studies were identiﬁed in correspondence 
with corresponding authors. 
Inclusion Criteria 
A study was included in the meta-analysis if it met all of the 
following criteria: (1) presented an association analysis between 
the DRD4 7R allele and AD/HD using either case–control or family-
based methods; (2) included (or the author provided) sufﬁcient 
data to calculate an odds ratio (OR) and variance for the association 
between AD/HD and the DRD4 7R allele; (3) reported data from an 
independent sample or was the largest dataset in a set of studies with 
overlapping samples; and (4) case–control studies employed 
healthy individuals for their control sample. For studies that used 
both case–control and family-based methods, results from 
case–control analyses were reported. Finally, for moderating anal­
yses, the study needed to provide a value for the relevant moderating 
variable. For non-independent samples, the largest sample that 
provided a value for the moderating variable was included. 
Identiﬁed Studies 
Of the 44 identiﬁed studies, a total of 17 studies were excluded from 
the primary analysis. Five studies conducted with Asian popula­
tions were excluded due to the absence of 7R alleles [Qian et al., 
2004; Brookes et al., 2005; Kim et al., 2005; Leung et al., 2005; Cheuk 
et al., 2006]. Four studies were excluded because the OR corre­
sponding to the association between the 7R allele and AD/HD could 
not be computed [Manor et al., 2002; Bhaduri et al., 2006; Brookes 
et al., 2006; Monuteaux et al., 2008]. Seven studies were excluded 
due to partially overlapping samples with larger samples [Smalley 
et al., 1998; Faraone et al., 1999; McCracken et al., 2000; Holmes 
et al., 2002; Kirley et al., 2002; Grady et al., 2003; Johnson et al., 
2008]. Lowe et al. [2004] was also excluded from the primary 
analysis but included in a moderating analysis as the proportion of 
AD/HD subtypes could not be calculated in Hawi et al. [2000]. One 
study was excluded because the control sample did not consist of 
healthy individuals [Ballon et al., 2007]. Note that a number of 
included case–control studies reported family-based association 
ORs [Hawi et al., 2000; Holmes et al., 2000; Mill et al., 2001; Roman 
et al., 2001; Gornick et al., 2007]. In these studies, only the data from 
the case–control association analyses were reported as they were 
associated with more precise sample information, included 
more participants, and are comparable to family-based results 
[Evangelou et al., 2006]. 
A total of 27 studies and 28 samples were included in the overall 
meta-analysis. Sixteen case–control and 12 family-based samples 
were included (see Tables IA and IB). AD/HD was diagnosed 
according to DSM-IV criteria in the majority of studies. Smith 
et al. [2003] did not use a formal diagnostic classiﬁcation system but 
their sample approximated DSM-IV criteria for AD/HD-C or 
ADHD-HI. Curran et al. [2001] used developmentally deviant 
scores on a brief behavioral questionnaire. DSM-III criteria were 
employed in three studies [Comings et al., 1999; Maher et al., 2002; 
El-Faddagh et al., 2004]. Johansson et al. [2008] used the ICD-10 
and made DSM-IV modiﬁcations allowing the sample to meet for 
AD/HD-I. Swanson et al. [1998] required participants to meet both 
DSM-IV and ICD-10 criteria. 
Some studies applied additional inclusion criteria including: (1) 
meeting criteria for DSM-IV AD/HD-C [LaHoste et al., 1996; Tahir 
et al., 2000; Carrasco et al., 2006]; (2) a therapeutic response to 
stimulant medication [Swanson et al., 1998; Sunohara et al., 2000 
Irvine Sample]; (3) absence of comorbid psychiatric disorders 
excluding ODD [Swanson et al., 1998; Muglia et al., 2000; Sunohara 
et al., 2000 both Samples]; and (4) male gender [Swanson et al., 
1998]. Common exclusionary criteria included low IQ or the 
presence of pervasive developmental disorder or neurological 
disorder. 
The majority of AD/HD samples were clinic-referred; three 
samples were community-based [Curran et al., 2001; Todd et al., 
2001; El-Faddagh et al., 2004]. In addition, most samples were 
child-based; two adult samples were included [Muglia et al., 2000; 
Johansson et al., 2008]. In case–control studies, control samples 
were selected using a variety of different methods including healthy 
blood donors, healthy siblings, paternity testing services and 
matched controls from epidemiological studies. In several studies, 
AD/HD was not formally assessed in the control sample; thus, some 
control subjects may have met diagnostic criteria for the disorder. 
Effect Size and Within Study Variance 
In case–control studies the OR is the ratio of the odds of having the 
DRD4 7R allele to non-7R alleles in the ADHD group compared to 
controls. Similarly, the OR for haplotype-based haplotype relative 
risk (HHRR) studies was the ratio of the odds of parents transmit­
ting the 7R allele to non-7R allele transmissions to AD/HD cases, 
compared to the non-transmission of the DRD4 7R and non-7R 
alleles. For transmission disequilibrium test (TDT) studies the 
method reported by Lohmueller et al. [2003] was followed. Speciﬁ­
cally, to compute the OR for TDT studies, the frequency that a 
heterozygous parent passed on the DRD4 7R allele to their affected 
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offspring was divided by the frequency that the allele was not passed 
to their affected offspring. Such a method is considered asymptoti­
cally equivalent to calculating an OR in a case–control study, as in a 
large population of control participants the expected transmission 
ratio would approach 50:50 [Lohmueller et al., 2003]. The ORs for 
both study types were then converted to log ORs and the log OR 
variance within case–control and HHRR studies was calculated by 
summing the reciprocals of the 7R allele and non-7R allele frequen­
cies in cases and controls and for transmitted and non-transmitted 
alleles, respectively. The variance in TDT studies was calculated 
assuming a large control sample. Thus, the sum of the reciprocals 
for the frequency of the transmitted risk allele and non-transmis­
sion of the risk allele were considered asymptotically equivalent to 
the sum of the reciprocal from each cell of a case–control study 
[Lohmueller et al., 2003]. 
Statistical Analysis 
Meta-analysis of case–control, HHRR and TDT studies was con­
ducted using Comprehensive Meta-Analysis (Version 2.0, BIO­
STAT, Englewood, NJ). Given that the samples and methods 
employed between studies are variable, it is assumed that the effect 
size from each study is a sample from a distribution of true effects 
[Borenstein et al., 2009]. Thus, a random effects model was used to 
estimate the mean of all relevant true effects [Borenstein et al., 2009] 
and the mean effect of moderator variables. Compared to a ﬁxed 
effects model, a random effects model allows inferences about 
population parameters including the effect size and regression 
coefﬁcients. The presence of heterogeneity in effect sizes between 
studies was tested using the c2-based Q-statistic. Heterogeneity was 
also measured with T2 and t which are estimates of the variance and 
standard deviation of true effects using the DerSimonian and Laird 
[1986] method. The amount of heterogeneity was quantiﬁed using 
I2, which measures the proportion of total variation that reﬂects real 
differences in the variability between studies in observed effect size 
[Borenstein et al., 2009]. 
Subgroup analysis and meta-regression analyses were utilized to 
examine the inﬂuence of categorical and continuous moderating 
variables on observed effect size. Subgroup analyses utilized a 
mixed-effects model, where T2 was calculated separately using a 
random effects model within subgroups and using a ﬁxed effects 
model between subgroups [Borenstein et al., 2009]. If a subgroup 
had fewer than ﬁve studies, then T2 was pooled across subgroups 
using a random-effects model, consistent with the recommenda­
tion from Borenstein et al. [2009]. A Q-test was used to test for 
heterogeneity across subgroups. 
A method of moments meta-regression was used to calculate the 
following model. Following notation by Raudenbush and Bryk 
[2002]:dj ¼ g0 þ g1W1j þ uj þ ejwhere dj is the odds ratio of 
study j, g0 and g1 are regression coefﬁcients; W1j is a study 
characteristic predicting effect sizes (e.g., proportion of AD/HD­
C individuals in a sample); and uj is the between studies random 
error which is not predicted by the study characteristic for which we 
assume uj � N (0, t2) and t2 is the between studies variance and ej is 
sampling error associated with the estimate (i.e., dj) of the popula­
tion effect size d, for study j, for which we assume ej � N (0, Vj). Here 
Vj is considered ‘‘known’’ and is the sampling variance for dj. In this 
FIG. 1. Forest plot of OR and pooled OR for association studies 
between AD/HD and the DRD4 7R allele. 
model, g0 represents the estimated effect size when W1j is equal to 
zero, and g1 indicates the amount of change in the effect size for a 
one-unit increase in W1j [Feinn et al., 2005]. Two-tailed z-tests were 
used to assess the impact of the moderating variables on effect size. 
An analogous index for proportion of variance explained was 
calculated; (R2 ¼ T2 ) to describe the proportion analog explained =T2 Total 
of systematic, between studies variance that is explained by the 
presence of the moderating variable [Borenstein et al., 2009]. Alpha 
was set to 0.05 for hypothesized analyses and reduced to 0.007 for 
exploratory meta-regression and sub-group analyses using a Bon­
feronni adjustment. 
RESULTS 
See Tables IA and IB for a summary of included studies. Twenty-
eight independent samples met inclusion criteria to estimate the 
mean effect size for the association between the DRD4 7R allele and 
AD/HD. A total of 1,688 identiﬁed AD/HD cases and 2,864 control 
subjects drawn from case–control studies were included in the 
meta-analysis. In family-based studies, approximately 1,3461 af­
fected individuals participated. Fewer individuals in each sample 
were included in TDT analyses as they require a parent to be 
heterozygous for the allele of interest. 
In the absence of a moderating variable, the unconditional model 
produced a log OR of 0.29 for g0. This corresponds to an OR of 
1.33 (95% CI ¼ 1.16–1.53, z ¼ 4.04, P ¼ 0.00005; Fig. 1). Neither 
visual inspection of a funnel plot nor Egger’s funnel plot statistic 
1The number 1,346 reflects the combined sample size from family-based 
studies with the exception of Arcos-Burgos et al. 2004 as the number of 
individuals with AD/HD from this study was not reported. 
TABLE II. Study Characteristics Examined as Potential Moderating Variables of Effect Size 
Moderator g1 SE z dfresidual P 
Transformeda proportion of AD/HD-C in AD/HD sample 1.47 0.55 2.67 13 0.008 
Proportion of AD/HD-C in AD/HD sample 0.85 0.28 3.02 13 0.003 
Transformedb proportion of AD/HD-I in AD/HD sample -0.88 0.38 -2.28 13 0.023 
Proportion of AD/HD-I in AD/HD sample -0.90 0.43 -2.09 13 0.037 
DRD4 7R allele frequency in AD/HD sample 0.99 2.72 0.37 14 0.715 
7R Allele frequency in control sample -5.02 0.92 -5.48 14 0.000 
Proportion of AD/HD males in AD/HD sample 0.52 0.81 0.64 8 0.523 
Log mean AD/HD age -0.18 0.21 -0.85 10 0.396 
The intercept for each analysis is not presented as the unconditional model demonstrated an overall association between the risk allele and the disorder, and the intercept for all moderating analyses 
varied substantially. In addition, given that the coverage of some covariates near the intercept were lacking, estimates of the intercept were considered extrapolations beyond available data.a1/(2 - X). 
bHX. 
[P ¼ 0.062; Egger et al., 1997] indicated the presence of publication 
bias. In addition, Rosenthal’s fail-safe N suggests that 227 
additional studies with a mean OR of 1.0 would need to be added 
to the analysis before the effect would be no longer signiﬁcant. ORs 
ranged from 1.30 to 1.36 and remained statistically signiﬁcant when 
each study was removed from the analysis, one at time, indicating 
that no one study produced the signiﬁcant overall effect. In the 
unconditional model, the variability in observed effect size 
between studies was greater than would be expected if each study 
shared a common effect (Q ¼ 54.24; P ¼ 0.001). Furthermore, I2 ¼ 
50.22 suggests that approximately half of the observed variability in 
effect size was systematic in nature. This indicates that moderating 
variables, such as AD/HD subtype, may account for the heteroge­
neity in effect sizes between studies. In order to test for this, the 
unconditional model was expanded to include moderating varia­
bles. Table II displays a summary of the results from these analyses. 
To test the primary hypothesis that the DRD4 7R allele is more 
strongly associated with AD/HD-C compared to other AD/HD 
subtypes, the proportion of AD/HD-C individuals within the AD/ 
HD sample was entered into the equation as a moderating variable. 
Given the proportional nature of this variable and that multiple 
studies included only AD/HD-C individuals, the proportion of AD/ 
HD-C individuals within reporting studies was negatively skewed, 
thus the reciprocal of 2 -X was applied to normalize the distribu­
tion.2 Increases in the transformed proportion of AD/HD-C in­
dividuals in the AD/HD sample predicted increases in the observed 
log OR (see Fig. 2). The transformed proportion of AD/HD-C 
individuals in the AD/HD sample accounted for 95% of the 
systematic variability in the observed ORs between studies. This 
was consistent with the untransformed proportion of AD/HD-C. 
These ﬁndings were mirrored by the proportion of AD/HD-I 
individuals in the AD/HD sample. The distribution of the propor­
tion of the AD/HD-I variable was positively skewed and a square 
root transformation was applied to normalize the distribution.3 
Increases in the square root transformation of the proportion of 
2Where X is the proportion of individuals diagnosed with AD/HD-C.
 
When X ¼ 1 the proportion was revised to X1 ¼ 2v - 1/2v; where v is the
 
AD/HD sample size.
 
3When the proportion of individuals with AD/HD-I was zero, the
 
proportion was revised to 1/2v; where v is the AD/HD sample size.
 
FIG. 2. Random-effects meta-regression analysis of study log OR 
on the transformed proportion AD/HD-C individuals in the AD/HD 
sample. The size of each data point reﬂects the relative weight of 
each study. 
AD/HD-I individuals in the AD/HD sample was associated with a 
decreased log OR (see Fig. 3). This ﬁnding was consistent with the 
effect of the non-transformed proportion of the AD/HD-I variable 
on observed log OR. 
Next, to explore whether study design accounted for variability 
in effect size, studies were dichotomized into either case–control or 
family-based design. Though effect sizes between studies were not 
signiﬁcantly different (Q ¼ 2.76; P ¼ 0.097), case–control studies 
had a larger mean effect size and a larger proportion of variability 
in observed effects (OR ¼ 1.46; 95% CI ¼ 1.19–1.79; z ¼ 3.66; 
I2P ¼ 0.0002; ¼ 62.04) compared to family-based analyses 
(OR ¼ 1.17; 95% CI ¼ 1.00–1.38; z ¼ 1.94; P ¼ 0.052; I2 ¼ 13.04). 
Exploratory meta-regression analyses examined variability in 
case–control studies. Allele frequency in the AD/HD sample did 
not predict observed log OR, whereas increases in the allele fre­
quency in the control sample was associated with decreases in the 
observed log OR (see Fig. 4). Within case–control studies, the allele 
frequency in the control sample accounted for approximately 
100%4 of the systematic variability in observed effect size between 
4The R2 theoretically ranges from 0 to 1 in the population;analog 
however, sampling error may cause the index to fall outside this 
range. In the present study, R2 ¼ 1:30, the value was set to 1.0 analog 
[Borenstein et al., 2009]. 
FIG. 3. Random-effects meta-regression analysis of study log OR 
on the transformed proportion of AD/HD-I individuals in the AD/ 
HD sample. The size of each data point reﬂects the relative 
weight of each study. 
FIG. 4. Random-effects meta-regression analysis of case–control 
study log OR on the proportion of the DRD4 7R allele frequency in 
the control sample. The size of each data point reﬂects the 
relative weight of each study. 
studies, whereas separately, the allele frequency in the AD/HD 
population only accounted for 19%. 
Exploratory analyses were also conducted to examine if other 
variables were associated with the variability in effect sizes between 
studies. In subgroup analyses, studies drawing from Mexico, Brazil, 
Chile and Colombia were not signiﬁcantly different from other 
studies (Q ¼ 0.07; P ¼ 0.407). In addition, studies using DSM-IV 
were not signiﬁcantly different than studies using other diagnostic 
approaches (Q ¼ 0.88; P ¼ 0.348). In meta-regression, neither the 
proportion of males nor the log of the mean age of the AD/HD 
sample5 predicted variability in observed effect size between studies. 
DISCUSSION 
The present meta-analysis examined the association of the DRD4 
7R allele with AD/HD by combining 16 case–control and 12 family-
based samples, which together included over 3,000 AD/HD cases 
and over 2,800 controls. The overall mean OR between the DRD4 
7R allele and AD/HD was 1.33. This indicates that the DRD4 7R 
5Mean age of the AD/HD sample was severely positively skewed. Thus a 
log transformation was applied to normalize the distribution. 
allele increases the odds that an individual is diagnosed with AD/ 
HD by 33%. This is in line with recent meta-analyses on the same 
topic that used slightly different inclusion criteria [Faraone et al., 
2005; Li et al., 2006; Gizer et al., 2009]. 
Consistent with recent meta-analyses [Li et al., 2006; Gizer et al., 
2009], the magnitude of association varied signiﬁcantly between 
studies. In an extension of previous topical meta-analyses and 
consistent with this study’s primary hypothesis, increases in the 
proportion of AD/HD-C individuals within the AD/HD sample 
were associated with an increase in the magnitude of association 
between the DRD4 7R allele and AD/HD. Findings suggest that 
including only AD/HD-C individuals in an analysis would increase 
the OR from 1.22 to 1.79, assuming 55% of the AD/HD sample met 
criteria for AD/HD-C [Lahey et al., 1994]. Conversely, as the 
proportion of AD/HD-I individuals in the AD/HD sample in­
creased, the observed OR decreased. Taken together, results were 
consistent with the hypothesis that the DRD4 7R allele is more 
strongly associated with AD/HD-C compared to AD/HD-I. The 
relative proportion of the two predominant AD/HD subtypes in the 
AD/HD sample accounted for the majority of systematic variability 
between reporting studies. Together, ﬁndings suggest that hypo-
functioning in mesocortical and mesolimbic dopaminergic path­
ways may better characterize the etiology of AD/HD-C compared to 
AD/HD-I [Sagvolden et al., 2005]. This is in line with ﬁndings that 
the DAT1 10-repeat allele is more strongly associated with AD/HD­
C than AD/HD-I [e.g., Waldman et al., 1998]. Furthermore, this 
meta-analysis suggests that reducing the AD/HD phenotypic het­
erogeneity may lead to the discovery of AD/HD etiological subtypes 
or possibly distinct disorders [e.g., Milich et al., 2001]. No other 
sample characteristics accounted for a signiﬁcant proportion of 
true between studies variance. 
In addition to sample characteristics, the association between 
study methodology and magnitude of effect size was explored. In 
contrast to Li et al. [2006], case–control studies did not have a 
signiﬁcantly larger effect size than family-based studies, but there 
was a trend in this direction. Given that results of case–control 
studies may be biased by population stratiﬁcation [Cardon and Bell, 
2001], the relationship between 7R allele frequencies in the AD/HD 
and control samples and OR was examined. The allele frequency in 
the AD/HD sample was not related to the observed OR whereas the 
allele frequency in the control population did predict observed OR 
and accounted for close to all of the systematic variability of 
observed ORs between case–control studies. Given that the DRD4 
allele frequencies vary substantially across ethnic groups [e.g., 
Chang et al., 1996] and that the association between the 7R allele 
and AD/HD may be dynamic [Shaw et al., 2007], the appropriate­
ness of the control sample in case–control studies is of critical 
importance. Failure to appropriately control for such character­
istics may have inﬂuenced the variability in ﬁndings. 
These ﬁndings provide guidance for further study. First, indi­
cators for the quality of AD/HD phenotyping are underreported in 
the literature. Future studies would be enhanced by: including 
information related to the psychometric properties of their assess­
ments; describing how assessments are combined to form a diag­
nosis; reporting how many cases and controls did not meet criteria 
for study inclusion; and by presenting descriptive sample statistics 
for both cases and controls. In terms of genotyping, few studies 
adequately reported tests of Hardy–Weinberg equilibrium [Gizer 
et al., 2009]. Future studies should report such information as it 
may help to explain variability between study ﬁndings. Though this 
meta-analysis included a relatively large number of samples, values 
for covariates of interest were often unavailable. For instance, like 
AD/HD subtype, differences in the rates of Conduct Disorder 
within and between samples may account for heterogeneity in 
candidate gene association studies [Thapar et al., 2006]; however, 
too few studies presented the rate of conduct disorder within their 
sample to be examined in this meta-analysis. In addition, values of 
covariates for TDT studies were attained from summary statistics 
that were based on the sample at-large and not only individuals 
included in the TDT analysis. Future research should stratify results 
based on potential moderating variables [Li et al., 2006] from the 
sample or sub-sample for which the results are based. 
These ﬁndings also need to be considered in light of the limi­
tations inherent in meta-regression analysis and subgroup analysis 
[see Thompson and Higgins, 2002 for a review]. First, values for 
moderating variables were not randomly assigned to studies; thus, 
relationships may be related to confounding bias. Second, meta­
regression analyses examining sample characteristics deal with 
sample averages between studies and not individual level data 
within studies, thus observed relationships between studies are not 
necessarily found within studies (e.g., ecological bias). For instance, 
though some evidence suggests that the relationship between AD/ 
HD and the DRD4 7R allele may reduce with age [Shaw et al., 2007], 
limited between study variability may have masked this association, 
which may be present within studies. This limitation can be 
attenuated through large collaborative efforts or by data stratiﬁed 
by moderating variables of interest. Finally, a practical limitation of 
meta-analysis and especially meta-regression is that access to 
observed effect size, its variance, and values for covariates are 
necessary. 
Despite these limitations, such ﬁndings support the argument 
[e.g., Milich et al., 2001] that AD/HD-C and AD/HD-I (with few to 
no hyperactive–impulsive symptoms) may result from distinct 
etiological pathways. Further delineating samples based on symp­
toms related to Sluggish Cognitive Tempo [e.g., McBurnett et al., 
2001] may allow for greater speciﬁcity in identifying shared and 
distinct pathways to distinct behavioral phenotypes. These ﬁndings 
also suggest that reducing the phenotypic variability within AD/HD 
may help to increase statistical power to detect candidate genes in 
molecular genetic studies. 
By pooling summary data from a relatively large number of 
association studies, evidence suggests that the DRD4 7R allele is 
more strongly related to AD/HD-C compared to AD/HD-I. These 
ﬁndings suggest that etiological theories of AD/HD, which are 
primarily based on AD/HD-C individuals, may fall short in identi­
fying appropriate candidate susceptibility genes for AD/HD-I. 
Additionally, given that the majority of genetic studies of AD/HD 
are conducted on clinical samples, which are disproportionally 
diagnosed with AD/HD-C [Lahey et al., 1994], such investigations 
may lack sufﬁcient power to identify unique vulnerability genes 
associated with AD/HD-I. Therefore, exploratory genome wide 
association studies may have the potential to identify genes that are 
more replicable and have a stronger association [Gizer et al., 2009] 
for this group of individuals. To guide candidate gene studies, 
future research should look to elucidate the neurobiological under­
pinnings of severe inattentive symptomatology in the absence of 
hyperactivity–impulsivity so that the genetic underpinnings of this 
symptom presentation may be better understood. To the extent that 
AD/HD-C and AD/HD-I (with few or no hyperactivity–impulsivity 
symptoms) have unique etiological pathways, there would be 
sufﬁcient evidence to categorize these AD/HD subtypes as separate 
disorders [e.g., Milich et al., 2001]. 
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